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Background
Small non-coding micro-RNAs (miRNA) are important
post-transcriptional regulators of mammalian gene
expression. More recently, miRNAs have been described
that regulate key elements of the adaptive immune
response, such as T-cell development and activation (miR-
181) and antigen presentation and development in B-cells
(miR-155. miR-150), and various aspects of innate immu-
nity (miR-146). We examined whether DNA vaccine vec-
tors co-expressing miRNA with Env antigen could
influence the magnitude or quality of the immune
responses to Env in mice.
Methods
Human miR-155 and flanking regions from the non-pro-
tein encoding gene microRNA host gene 2 (MIRHG2),
were introduced into an artifical intron within an enve-
lope expression vector. Expression of miR-155 and Env
was examined by Northern and Western Blot respectively.
Using miR-155 sequences as a scaffold, we incorporated
novel miRNAs encoded to silence expression of host anti-
viral proteins, or alternatively, to mimic other endog-
enous, immunomodulatory miRNAs.
Results
The human miR-155 was efficiently expressed and cor-
rectly processed from an upstream intron within an Env-
expressing DNA vaccine plasmid in human cell lines.
Locating the miRNA expression sequences within the
intron did not reduce Env expression. Substitution of the
native miR-155 guide sequence enabled the targeting of
exogenous marker genes, EGFP and ds-Red. Targeting of
cellular genes thought to influence Env expression in vivo,
such as PKR and SFRS1, significantly down-modulated
expression of targeted genes but failed to increase Env
expression in vitro. In an alternative strategy, vaccine vec-
tors delivering immunomodulatory miRNAs such as miR-
155 were used to vaccinate BALB/c mice and the genera-
tion of Env-specific T-cells and effective antibody
responses was measured.
Conclusion
This study provides evidence that native and engineered
miRNAs can be successfully co-expressed with HIV-1 Env
antigens. The further characterisation of immunomodula-
tory miRNAs may enable the development of vaccine vec-
tors better able to shape the immune responses to HIV-1
vaccines towards protective correlates of immunity.
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